In this issue:
Ferric carboxymaltose in HF with iron deficiency
Semaglutide in HFPEF and obesity
Clinical characteristics and HF outcomes: LVEF thresholds and inflection points
Obesity in HFPEF with or without diabetes
VAI and HF risk, late-life cardiac structure and function
Blinded withdrawal of long-term empagliflozin or placebo in HF
Cardiac and metabolic effects of dapagliflozin in HFPEF
Age, sex and outcomes in HFREF
5-year mortality in patients managed with magnetically levitated LVAD
MRA underutilisation in HFREF
Please login below to download this issue (PDF)